Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label follow-up of tofacitinib in juvenile idiopathic arthritis
2011-004915-22Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in juvenile idiopathic arthritis (JIA), sponsored by Pfizer. Primary endpoints: Long-term safety and tolerability of tofacitinib and Growth and physical development. Started May 2012; status: completed.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2011-004915-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004915-22.